Ammonium Tetrathiomolybdate (ATTM) - Phase 2 clinical program (partner)
Copper Chelator
cGMP API - Type II DMF
Oral Capsule - Phase 1 & 2 clinical studies
Ammonium tetrathiomolybdate (copper chelator), a type of chelating and antiangiogenesis agent, is being studied in the treatment of many types of cancer. Known for its ability to remove extra copper from the body, ammonium tetrathiomolybdate may prevent the growth of new blood vessels that tumors need to grow and may also possess the ability to kill cancer cells.
An oral formulation is currently in development for a Phase 2 clinical trial in breast cancer patients.
Clinical Studies
NCT06134375 A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT00195091 Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
References (over 500 total)
The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer, Ni Zeng, Ye Wang, Yuan Wan. Hongyu Wang, Nan Li. Clin Med Insights Oncol. 2023 Nov 22:17:11795549231204612. doi: 10.1177/11795549231204612. PMID: 38023286.
Copper metabolism in cell death and autophagy, Qian Xue, Rui Kang, Daniel J Klionsky, Daolin Tang, Jinbao Liu, Xin Chen. Autophagy. 2023 Aug;19(8):2175-2195. doi: 10.1080/15548627.2023.2200554. Epub 2023 Apr 16. PMID: 37055935.
Ammonium tetrathiomolybdate relieves oxidative stress in cisplatin-induced acute kidney injury via NRF2 signaling pathway. Hao Qi, et.al. Cell Death Discov. 2023 Jul 25;9(1):259. doi: 10.1038/s41420-023-01564-1. PMID: 37491360.
The copper chelator ammonium tetrathiomolybdate inhibits the progression of experimental endometriosis in TNFR1-deficient mice. Rocío Ayelem Conforti, María Belén Delsouc, Ana Sofia Zabala, Sandra Silvina Vallcaneras, Marilina Casais. Sci Rep. 2023 Jun 26;13(1):10354. doi: 10.1038/s41598-023-37031-1. PMID: 37365216
Tetrathiomolybdate as an old drug in a new use: As a chemotherapeutic sensitizer for non-small cell lung cancer. Li Y, Fang M, Xu Z, Li X. J Inorg Biochem. 2022 Aug;233:111865. doi: 10.1016/j.jinorgbio.2022.111865. Epub 2022 May 19. PMID: 35623139.
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. Shribman S, Marjot T, Sharif A, Vimalesvaran S, Ala A, Alexander G, Dhawan A, Dooley J, Gillett GT, Kelly D, McNeill A, Warner TT, Wheater V, Griffiths W, Bandmann O; British Association for the Study of the Liver Rare Diseases Special Interest Group. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):560-575. doi: 10.1016/S2468-1253(22)00004-8. Epub 2022 Apr 13. PMID: 35429442.
Copper chelation therapy inhibits renal fibrosis by modulating copper transport proteins. Saifi MA, Godugu C. Biofactors. 2022 Mar 24. doi: 10.1002/biof.1837. PMID: 35322483.